Urinary Incontinence Treatment Network (UITN)
尿失禁治疗网络 (UITN)
基本信息
- 批准号:8147970
- 负责人:
- 金额:$ 19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-30 至 2012-08-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAutologousBaltimoreBehavior TherapyClient satisfactionClinicalClinical ResearchDataData CollectionEffectivenessEnrollmentFollow-Up StudiesFrequenciesFunctional disorderFundingGoldGuidelinesHuman ResourcesIncontinenceIndustryInjuryLiteratureManuscriptsMarketingMarylandMedicalMorbidity - disease rateObservational StudyOperative Surgical ProceduresPainPatient Self-ReportPatientsPerformancePharmacotherapyPhaseProceduresPtosisQuality of lifeRandomizedRandomized Clinical TrialsRandomized Controlled TrialsRecommendationRecording of previous eventsResearch PersonnelResourcesRiskSafetySisterStressStress Urinary IncontinenceStudy SubjectSymptomsTimeTransplanted tissueUniversitiesUrethraUrge IncontinenceUrinary IncontinenceUrodynamicsWomanWorld Health Organizationarmbasecohortcomparative efficacyefficacy evaluationexperiencefollow-upimprovedminimally invasiveprevention evaluationprotocol developmentrepairedresponseuptakeworking group
项目摘要
DESCRIPTION (provided by applicant): This proposal is submitted in response to RFA-DK-06-501 for continuation of the Urinary Incontinence Treatment Network (UITN) Clinical Center at University of Maryland Baltimore (UMB). Phase II will focus on conduct of the Trial of Mid-Urethral Slings (TOMUS) trial as well as continuation of the observational follow- up studies for the SISTEr and BE-DRI studies (i.e. E-SISTEr and E-BE-DRI) of Phase I. Primary Aims of TOMUS are to compare objective and subjective cure rates for stress incontinence at 12 and 24 months between the retropubic and transobturator midurethral sling (MUS) procedures.The retropubic approach, with the longest history and most available data on efficacy and safety of all MUS procedures, is generally accepted as the gold standard. The transobturator approach stays out of the retropubic space and offers the most potential for improving the rare but significant risks associated with the original retorpubic procedure. Performance of these procedures is increasing rapidly with limited data available on safety and efficacy. Therefore, this study will compare the efficacy and safety of the retropubic and transobturator (inside-out and outside-in) procedures in a 2-arm RCT. 588 women with stress Ul will be enrolled; 65 patients at this clinical center (CC). The Primary Aim of E-SISTEr is to compare long-term effectiveness and durability (60 mos) of the Burch colposuspension and autologous fascial sling for treatment of stress Ul in a randomized cohort of 655 women; 64 are enrolled at this CC. The Primary Aim of E-BE-DRI is to examine long-term durability (26 mos) of the addition of behavioral treatment to drug therapy for treatment of urge Ul in a randomized cohort of 307 women; 26 are enrolled at this CC. For all studies, the CC is responsible for patient enrollment and follow-up, treatment, data collection and management. CC investigators participate in network activities, including protocol development, standing committees and work groups, manuscripts and presentations. Based on UMB's successful recruitment and retention of study subjects in the first funding cycle, UMB has the experience, resources, personnel and clinical volume to be successful in TOMUS. The UITN is a multi- disciplinary, multi-center group of Investigators dedicated to high impact clinical research regarding the prevention, evaluation and management of Ul to improve the quality of life for adults.
描述(由申请人提供):本提案是为了响应RFA-DK-06-501,继续在马里兰大学巴尔的摩分校(UMB)建立尿失禁治疗网络(UITN)临床中心而提交的。第二阶段将集中于进行尿道中间吊带(TOMUS)试验,以及对第一阶段的SISTER和BE-DRI研究(即E-SISTER和E-BE-DRI)的观察性随访研究的继续。TOMUS的主要目标是比较12个月和24个月耻骨后和经膀胱膀胱吊带(MUS)手术的压力性尿失禁的客观和主观治愈率。耻骨后入路是历史最长、所有MUS手术的有效性和安全性方面可获得最多数据的方法,被公认为黄金标准。经耻骨上突入路远离耻骨后间隙,最有可能改善与原始耻骨后手术相关的罕见但重大的风险。这些程序的性能正在迅速提高,有关安全性和有效性的现有数据有限。因此,本研究将比较双臂RCT中耻骨后和经耻骨后(由内向外和由外向内)手术的有效性和安全性。588名有应激性UL的女性将被纳入研究;65名患者在该临床中心(CC)。E-SISTER的主要目的是比较Burch悬吊术和自体筋膜悬吊术治疗应激性尿失禁的长期有效性和耐用性(60个月),随机选择655名女性作为研究对象。参加了这项研究。E-BE-DRI的主要目的是在307名妇女的随机队列中检验在药物治疗的基础上加用行为疗法治疗UL的长期持久性(26个月);26名妇女在这项CC中登记。对于所有研究,CC负责患者登记和随访、治疗、数据收集和管理。协调委员会调查员参加网络活动,包括制订礼仪、常设委员会和工作组、手稿和陈述。基于UMB在第一个资助周期成功招募和保留研究对象,UMB拥有在TOMUS取得成功的经验、资源、人员和临床数量。UITN是一个多学科、多中心的研究小组,致力于UL的预防、评估和管理方面的高影响力临床研究,以提高成年人的生活质量。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
History and Future of Multi-Institutional Clinical Trials in Urinary Incontinence.
尿失禁多机构临床试验的历史和未来。
- DOI:10.1007/s11884-011-0094-7
- 发表时间:2011
- 期刊:
- 影响因子:0.4
- 作者:Chai,TobyC
- 通讯作者:Chai,TobyC
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TOBY C CHAI其他文献
TOBY C CHAI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TOBY C CHAI', 18)}}的其他基金
Human Bladder Urothelial Cell Structure and Function in Bladder Hypersensation
膀胱过敏中的人膀胱尿路上皮细胞结构和功能
- 批准号:
7983871 - 财政年份:2009
- 资助金额:
$ 19万 - 项目类别:
Human Bladder Urothelial Cell Structure and Function in Bladder Hypersensation
膀胱过敏中的人膀胱尿路上皮细胞结构和功能
- 批准号:
7856568 - 财政年份:2009
- 资助金额:
$ 19万 - 项目类别:
Human Bladder Urothelial Cell Structure and Function in Bladder Hypersensation
膀胱过敏中的人膀胱尿路上皮细胞结构和功能
- 批准号:
7132750 - 财政年份:2006
- 资助金额:
$ 19万 - 项目类别:
Human Bladder Urothelial Cell Structure and Function in Bladder Hypersensation
膀胱过敏中的人膀胱尿路上皮细胞结构和功能
- 批准号:
7667240 - 财政年份:2006
- 资助金额:
$ 19万 - 项目类别:
Human Bladder Urothelial Cell Structure and Function in Bladder Hypersensation
膀胱过敏中的人膀胱尿路上皮细胞结构和功能
- 批准号:
7278843 - 财政年份:2006
- 资助金额:
$ 19万 - 项目类别:
相似海外基金
Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
- 批准号:
MR/Y019458/1 - 财政年份:2024
- 资助金额:
$ 19万 - 项目类别:
Research Grant
Fabrication and Evaluation of Poly(glycerol sebacate) based small diameter vascular graft as a potent substitution for autologous vessels
基于聚(甘油癸二酸酯)的小直径血管移植物作为自体血管有效替代品的制造和评估
- 批准号:
2897580 - 财政年份:2023
- 资助金额:
$ 19万 - 项目类别:
Studentship
Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head
自体骨髓抽吸浓缩液治疗股骨头坏死
- 批准号:
10658324 - 财政年份:2023
- 资助金额:
$ 19万 - 项目类别:
Identifying multimodal biomarkers for autologous serum tears in the treatment of chronic postoperative ocular pain
识别治疗慢性术后眼痛的自体血清泪液的多模式生物标志物
- 批准号:
10794761 - 财政年份:2023
- 资助金额:
$ 19万 - 项目类别:
SBIR Phase II: An Injectable Protein Matrix to Enhance the Stability of Autologous Fat Grafts
SBIR II 期:可注射蛋白质基质,增强自体脂肪移植物的稳定性
- 批准号:
2304430 - 财政年份:2023
- 资助金额:
$ 19万 - 项目类别:
Cooperative Agreement
Application of Autologous Connective Tissue Sheets Created in Patients' Bodies to Pediatric Cardiac Valvuloplasty and Development of Dedicated Molds
患者体内自体结缔组织片在小儿心脏瓣膜成形术中的应用及专用模具的开发
- 批准号:
23K15543 - 财政年份:2023
- 资助金额:
$ 19万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
MICA: Strategy for heart repair in Duchenne Muscular Dystrophy (DMD) using genetically engineered autologous Mesoangioblasts
MICA:利用基因工程自体中成血管细胞修复杜氏肌营养不良症 (DMD) 的心脏的策略
- 批准号:
MR/X00466X/1 - 财政年份:2023
- 资助金额:
$ 19万 - 项目类别:
Fellowship
Planning a phase I study of minor salivary gland derived autologous MSCs for prevention of long-term radiation induced xerostomia
计划对小唾液腺来源的自体 MSC 进行 I 期研究,以预防长期辐射引起的口干症
- 批准号:
10720234 - 财政年份:2023
- 资助金额:
$ 19万 - 项目类别:
SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING
SBIR 第二阶段,主题 429:自体和同种异体细胞治疗制造的新范式
- 批准号:
10976161 - 财政年份:2023
- 资助金额:
$ 19万 - 项目类别:
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.
使用基序新表位肽脉冲的自体树突状细胞对携带带电 HLA-B 结合袋的非小细胞肺癌患者的治疗性疫苗接种策略进行评估。
- 批准号:
10721983 - 财政年份:2023
- 资助金额:
$ 19万 - 项目类别: